Trinity Biotech (NASDAQ:TRIB) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Rating) in a note issued to investors on Thursday. The brokerage set a “buy” rating on the stock.

Trinity Biotech Trading Down 1.7 %

Trinity Biotech stock opened at $0.87 on Thursday. Trinity Biotech has a 1 year low of $0.81 and a 1 year high of $1.55. The firm’s 50-day moving average is $1.01 and its 200-day moving average is $1.11. The company has a debt-to-equity ratio of 8.70, a quick ratio of 1.39 and a current ratio of 2.69. The company has a market cap of $32.97 million, a P/E ratio of -0.67 and a beta of 1.41.

Get Trinity Biotech alerts:

Institutional Trading of Trinity Biotech

Several hedge funds have recently made changes to their positions in TRIB. Atria Wealth Solutions Inc. acquired a new stake in Trinity Biotech in the first quarter worth $27,000. Virtu Financial LLC bought a new stake in Trinity Biotech in the 1st quarter valued at about $40,000. Whitefort Capital Management LP lifted its position in Trinity Biotech by 1,067.8% in the 1st quarter. Whitefort Capital Management LP now owns 409,517 shares of the company’s stock valued at $434,000 after purchasing an additional 374,449 shares during the last quarter. Hunter Associates Investment Management LLC boosted its stake in Trinity Biotech by 1.5% during the 4th quarter. Hunter Associates Investment Management LLC now owns 1,823,633 shares of the company’s stock valued at $1,809,000 after purchasing an additional 26,443 shares during the period. Finally, Renaissance Technologies LLC grew its position in Trinity Biotech by 2.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,503,336 shares of the company’s stock worth $1,842,000 after purchasing an additional 34,900 shares during the last quarter. Institutional investors own 18.41% of the company’s stock.

About Trinity Biotech

(Get Rating)

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O’Caoimh and Denis R.

Further Reading

• Get a free copy of the StockNews.com research report on Trinity Biotech (TRIB)
• Penny Stock Wag! Group Co. Has Solid Sell-Side Support
• Staples Stocks Get Lift From Conagra Results, New Highs In Sight
• SGH Bottomed, But Can It Reverse And Move Higher? 
• Is Pinterest Showing Signs of an Improving Ad Market?
• At 3x Earnings, Avis Budget Is Worth Taking for a Spin

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.